Immune checkpoint inhibitors for the treatment of melanoma.

Abstract

INTRODUCTION:

Immune checkpoint inhibitor (ICI) based immunotherapy is dramatically changing the management of many types of cancers including melanoma. In this malignancy, ICIs prolong disease and progression-free survival as well as overall survival of a percentage of treated patients, becoming the cornerstone of melanoma treatment.

AREAS COVERED:

In this review, first, we will describe the mechanisms of immune checkpoint activation and inhibition, second, we will summarize the results obtained with ICIs in melanoma treatment in terms of efficacy as well as toxicity, third, we will discuss the potential mechanisms of immune escape from ICI, and lastly, we will review the potential predictive biomarkers of clinical efficacy of ICI-based immunotherapy in melanoma.

EXPERT OPINION:

ICIs represent one of the pillars of melanoma treatment. The success of ICI-based therapy is limited by the development of escape mechanisms, which allow melanoma cells to avoid recognition and destruction by immune cells. These results emphasize the need of additional studies to confirm the efficacy of therapies, which combine different classes of ICIs as well as ICIs with other types of therapies. Furthermore, novel and more effective predictive biomarkers are needed to better stratify melanoma patients in order to define more precisely the therapeutic algorithms.

• Authors: Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 22 Issue 5 Pg. 563-576 (05 2022) ISSN: 1744-7682 [Electronic] England
• PMID: 35130816 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Immune Checkpoint Inhibitors

Topics

• Biomarkers
• Humans
• Immune Checkpoint Inhibitors (adverse effects)
• Immunotherapy (methods)
• Melanoma (pathology)